Society of Gynecologic Oncology Publications
- PARP inhibitors (PARPi) have shown have activity in the treatment of ovarian cancer. Previous studies documented activity in patients with germline (gBRCA) and tumor (tBRCA) BRCA mutations (BRCAm) for treatment in lieu of chemotherapy as well as in recurrent ovarian cancer as maintenance therapy. The recent data from four randomized phase 3 trials have established an important role for frontline PARPi maintenance therapy in ovarian cancer. While SOLO-1 only included BRCAm patients, PRIMA, VELIA, and PAOLA-1 enrolled broader patient populations.
- In December 2018, the Policy, Quality, and Outcomes Taskforce of the SGO convened a daylong seminar including experts in the field of PROs to further SGO's vision of integrating PROMs into routine clinical practice as a component of patient-centric care. Recognizing our role in managing cancer patients across the entire continuum of surgical and medical care, we believe gynecologic oncologists are uniquely positioned to make important contributions to this field and influence the delivery of care in the wider discipline of oncology.
- Health-related quality of life (HRQoL) has been increasingly recognized as a critical metric to ensure delivery of high quality, patient-centered cancer care. HRQoL can be measured in several ways, but often involves collecting patient reported outcomes (PROs). PROs collected on validated questionnaires are known as patient reported outcome measures (PROMs).
- The practice of gynecologic oncology is facing significant changes in reimbursement practices and health care delivery in the United States. As the only physicians trained to provide both complex surgical and medical treatment for women with gynecologic cancers, gynecologic oncologists are the ideal leaders for developing best practice models and outcome measures for women with gynecologic cancers. The Society of Gynecologic Oncology (SGO) created the Health Policy and SocioEconomic Committee (HPSC) in 2015 to spearhead society-based efforts to ensure leadership and participation in navigating this era of health care reform.